Testing blood tests for leftover colorectal cancer after surgery
Compares blood tests that detect tumor DNA in adults with colorectal cancer.
Plain-language title generated from the registry record
Registry title: GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Key facts
- Where
- Huddinge, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you had another type of cancer in the past 3 years?
Source: NCT06111105, who can take part
Where in Sweden
- Karolinska University HospitalHuddinge, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Claus Lindbjerg Andersen
- Trial code
- NCT06111105
- Record updated
- 4 May 2026
- Original description
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.Read full original descriptionShow less
GUIding Multi-moDal thErapies Against MRD by Liquid Biopsies in Colorectal Cancer - GUIDE.MRD-01-CRC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.
There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.
The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.
GUIDE.MRD-01-CRC is a part of the GUIDE.MRD project.
Inclusion: Colorectal cancer, UICC stage III; Has received curative-intent resection and is a candidate for adjuvant chemotherapy; Patient able to understand and sign written informed consent; Colorectal cancer liver metastasis; Planned for curative-intent treatment; Performance status 0-1.
Exclusion: Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included); Treated with neoadjuvant chemo-radiation therapy; Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome; Inflammatory bowel disease (Crohn's disease or ulcerative colitis); Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma); Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening; Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study; Colorectal cancer liver metastasis; Other cancer within the last 5 years; Verified distant metastases; No tissue sample available for the project, or tumor content in the tissue sample is <20%; Liver cirrhosis; Extrahepatic metastases; Intervention not performed with curative intent; No tissue available from CRLM or primary tumor.
Colorectal cancer stage III.